As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...

Credit: Bristol Myers Squibb. Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors. Data from the EMERGENT ...

New research finds that adults with schizophrenia spectrum disorders have high rates of comorbid mental and substance use disorders and significant social and economic disadvantages, and only 26% ...

Schizophrenia spectrum disorders significantly increase cardiovascular and metabolic disease risks, partly due to antipsychotic-induced weight gain and glucose dysregulation.

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies showed ...

If you live with schizophrenia, embracing self-care habits as part of your treatment plan can help you control symptoms, get good sleep, maintain meaningful relationships, and more. “Self-care for ...

How Does Cobenfy Work, and How Is It Different From Other Medicines Used to Treat Schizophrenia? An imbalance of brain chemicals called neurotransmitters may contribute to schizophrenia. Current ...

COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers ...